Analyst Recent Upgrades and Downgrades from Yesterday (August 24, 2025)
No specific upgrades or downgrades for LLY on August 24, 2025. Recent activity includes Ally Financial increasing holdings (positive signal) and Broadleaf Partners reducing shares (negative signal). Earlier in August: DZ Bank upgraded to Strong Buy (August 14); Leerink downgraded to Market Perform (August 7); Daiwa downgraded to Neutral (August 17) with PT $700.
Overall Market Sentiment
Consolidated sentiment for LLY stock is mixed but leans positive, with 58% of opinions positive (insider buys, earnings growth, drug pipeline), 32% negative (trial setbacks, high valuations), and 10% neutral.
Key Insights & Reasons
- Positive Drivers: Q2 earnings beat ($15.56B revenue, +38% YoY), raised FY2025 guidance ($60-62B revenue), multiple insider buys ($4-5M at ~$640-645), strong fundamentals (ROE 103.74%, EBITDA +82%), promising trials (e.g., lung cancer, Alzheimer’s). Analysts’ Strong Buy consensus (avg. PT $905-975, +27-39% upside).
- Negative Drivers: 14-18% stock drop post-oral weight-loss pill (orforglipron) underperformance vs. Novo Nordisk, high P/E (45.5-64.5), downgrades/PT cuts, tariff/regulatory risks.
- Consistent Themes: Obesity/GLP-1 competition (Mounjaro/Zepbound strength vs. pill disappointment), insider confidence signaling buy-the-dip, oversold indicators (RSI low, Bollinger Bands), sector rotation to healthcare, long-term EPS growth (22% annual to 2029, potential $1T cap).
Actionable Recommendation
There is strong possibility for LLY stock to go up across timeframes due to oversold conditions and insider buys:
- Day Trade: Yes, potential bounce near $700 support on volume spikes.
- Swing Trade: Yes, 10-15% rebound targeting $800 on reversal signals.
- Short Term: Yes, bullish options sentiment and earnings momentum for 20%+ gain.
- Long Term: Yes, 50%+ upside to $1,000+ on drug pipeline and growth forecasts; buy dip for compounding returns.